Search

Your search keyword '"Kench A"' showing total 78 results
Start Over Author "Kench A" Publisher american association for cancer research (aacr)
78 results on '"Kench A"'

1. Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Butler, Lisa M., primary, Mah, Chui Yan, primary, Machiels, Jelle, primary, Vincent, Andrew D., primary, Irani, Swati, primary, Mutuku, Shadrack M., primary, Spotbeen, Xander, primary, Bagadi, Muralidhararao, primary, Waltregny, David, primary, Moldovan, Max, primary, Dehairs, Jonas, primary, Vanderhoydonc, Frank, primary, Bloch, Katarzyna, primary, Das, Rajdeep, primary, Stahl, Jurgen, primary, Kench, James G., primary, Gevaert, Thomas, primary, Derua, Rita, primary, Waelkens, Etienne, primary, Nassar, Zeyad D., primary, Selth, Luke A., primary, Trim, Paul J., primary, Snel, Marten F., primary, Lynn, David J., primary, Tilley, Wayne D., primary, Horvath, Lisa G., primary, Centenera, Margaret M., primary, and Swinnen, Johannes V., primary

Published
2023
Full Text
View/download PDF

2. Data from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 4 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 5 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 2 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

Ricciardelli, Carmela, primary, Bianco-Miotto, Tina, primary, Jindal, Shalini, primary, Dodd, Thomas J., primary, Cohen, Penelope A., primary, Marshall, Villis R., primary, Sutherland, Peter D., primary, Samaratunga, Hemamali, primary, Kench, James G., primary, Dong, Ying, primary, Wang, Hong, primary, Clements, Judith A., primary, Risbridger, Gail P., primary, Sutherland, Robert L., primary, Tilley, Wayne D., primary, and Horsfall, David J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Tables 1-3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Butler, Lisa M., primary, Mah, Chui Yan, primary, Machiels, Jelle, primary, Vincent, Andrew D., primary, Irani, Swati, primary, Mutuku, Shadrack M., primary, Spotbeen, Xander, primary, Bagadi, Muralidhararao, primary, Waltregny, David, primary, Moldovan, Max, primary, Dehairs, Jonas, primary, Vanderhoydonc, Frank, primary, Bloch, Katarzyna, primary, Das, Rajdeep, primary, Stahl, Jurgen, primary, Kench, James G., primary, Gevaert, Thomas, primary, Derua, Rita, primary, Waelkens, Etienne, primary, Nassar, Zeyad D., primary, Selth, Luke A., primary, Trim, Paul J., primary, Snel, Marten F., primary, Lynn, David J., primary, Tilley, Wayne D., primary, Horvath, Lisa G., primary, Centenera, Margaret M., primary, and Swinnen, Johannes V., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legend from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

15. Data from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Butler, Lisa M., primary, Mah, Chui Yan, primary, Machiels, Jelle, primary, Vincent, Andrew D., primary, Irani, Swati, primary, Mutuku, Shadrack M., primary, Spotbeen, Xander, primary, Bagadi, Muralidhararao, primary, Waltregny, David, primary, Moldovan, Max, primary, Dehairs, Jonas, primary, Vanderhoydonc, Frank, primary, Bloch, Katarzyna, primary, Das, Rajdeep, primary, Stahl, Jurgen, primary, Kench, James G., primary, Gevaert, Thomas, primary, Derua, Rita, primary, Waelkens, Etienne, primary, Nassar, Zeyad D., primary, Selth, Luke A., primary, Trim, Paul J., primary, Snel, Marten F., primary, Lynn, David J., primary, Tilley, Wayne D., primary, Horvath, Lisa G., primary, Centenera, Margaret M., primary, and Swinnen, Johannes V., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

Ricciardelli, Carmela, primary, Bianco-Miotto, Tina, primary, Jindal, Shalini, primary, Dodd, Thomas J., primary, Cohen, Penelope A., primary, Marshall, Villis R., primary, Sutherland, Peter D., primary, Samaratunga, Hemamali, primary, Kench, James G., primary, Dong, Ying, primary, Wang, Hong, primary, Clements, Judith A., primary, Risbridger, Gail P., primary, Sutherland, Robert L., primary, Tilley, Wayne D., primary, and Horsfall, David J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table and Figure Legends from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, primary, Buchanan, Grant, primary, Jindal, Shalini, primary, Day, Tanya K., primary, Thomas, Mervyn, primary, Pickering, Marie A., primary, O'Loughlin, Melissa A., primary, Ryan, Natalie K., primary, Raymond, Wendy A., primary, Horvath, Lisa G., primary, Kench, James G., primary, Stricker, Phillip D., primary, Marshall, Villis R., primary, Sutherland, Robert L., primary, Henshall, Susan M., primary, Gerald, William L., primary, Scher, Howard I., primary, Risbridger, Gail P., primary, Clements, Judith A., primary, Butler, Lisa M., primary, Tilley, Wayne D., primary, Horsfall, David J., primary, and Ricciardelli, Carmela, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Butler, Lisa M., primary, Mah, Chui Yan, primary, Machiels, Jelle, primary, Vincent, Andrew D., primary, Irani, Swati, primary, Mutuku, Shadrack M., primary, Spotbeen, Xander, primary, Bagadi, Muralidhararao, primary, Waltregny, David, primary, Moldovan, Max, primary, Dehairs, Jonas, primary, Vanderhoydonc, Frank, primary, Bloch, Katarzyna, primary, Das, Rajdeep, primary, Stahl, Jurgen, primary, Kench, James G., primary, Gevaert, Thomas, primary, Derua, Rita, primary, Waelkens, Etienne, primary, Nassar, Zeyad D., primary, Selth, Luke A., primary, Trim, Paul J., primary, Snel, Marten F., primary, Lynn, David J., primary, Tilley, Wayne D., primary, Horvath, Lisa G., primary, Centenera, Margaret M., primary, and Swinnen, Johannes V., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, primary, Qu, Wenjia, primary, Song, Jenny Z., primary, Statham, Aaron L., primary, Patterson, Kate I., primary, Horvath, Lisa G., primary, Tabor, Bruce, primary, Coolen, Marcel W., primary, Hulf, Toby, primary, Kench, James G., primary, Henshall, Susan M., primary, Pe Benito, Ruth, primary, Haynes, Anne-Maree, primary, Mayor, Regina, primary, Peinado, Miguel A., primary, Sutherland, Robert L., primary, and Clark, Susan J., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 2 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Supplementary Figure 2 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Published
2023
Full Text
View/download PDF

24. Supplementary Table 2 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

David J. Horsfall, Wayne D. Tilley, Robert L. Sutherland, Gail P. Risbridger, Judith A. Clements, Hong Wang, Ying Dong, James G. Kench, Hemamali Samaratunga, Peter D. Sutherland, Villis R. Marshall, Penelope A. Cohen, Thomas J. Dodd, Shalini Jindal, Tina Bianco-Miotto, and Carmela Ricciardelli

Abstract

Supplementary Table 2 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Published
2023
Full Text
View/download PDF

25. Supplementary Figure Legend from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Figure Legend from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Table 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

27. Data from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

David J. Horsfall, Wayne D. Tilley, Robert L. Sutherland, Gail P. Risbridger, Judith A. Clements, Hong Wang, Ying Dong, James G. Kench, Hemamali Samaratunga, Peter D. Sutherland, Villis R. Marshall, Penelope A. Cohen, Thomas J. Dodd, Shalini Jindal, Tina Bianco-Miotto, and Carmela Ricciardelli

Abstract

Background: Knowledge of preanalytic conditions that biospecimens are subjected to is critically important because novel surgical procedures, tissue sampling, handling, and storage might affect biomarker expression or invalidate tissue samples as analytes for some technologies.Methods: We investigated differences in RNA quality, gene expression by quantitative real-time PCR, and immunoreactive protein expression of selected prostate cancer biomarkers between tissues from retropubic radical prostatectomy (RRP) and robot-assisted laparoscopic prostatectomy (RALP). Sections of tissue microarray of 23 RALP and 22 RRP samples were stained with antibodies to androgen receptor (AR) and prostate-specific antigen (PSA) as intersite controls, and 14 other candidate biomarkers of research interest to three laboratories within the Australian Prostate Cancer BioResource tissue banking network. Quantitative real-time PCR was done for AR, PSA (KLK3), KLK2, KLK4, and HIF1A on RNA extracted from five RALP and five RRP frozen tissue cores.Results: No histologic differences were observed between RALP and RRP tissue. Biomarker staining grouped these samples into those with increased (PSA, CK8/18, CKHMW, KLK4), decreased (KLK2, KLK14), or no change in expression (AR, ghrelin, Ki67, PCNA, VEGF-C, PAR2, YB1, p63, versican, and chondroitin 0-sulfate) in RALP compared with RRP tissue. No difference in RNA quality or gene expression was detected between RALP and RRP tissue.Conclusions: Changes in biomarker expression between RALP and RRP tissue exist at the immunoreactive protein level, but the etiology is unclear.Impact: Future studies should account for changes in biomarker expression when using RALP tissues, and mixed cohorts of RALP and RRP tissue should be avoided. Cancer Epidemiol Biomarkers Prev; 19(7); 1755–65. ©2010 AACR.

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 5 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Figure 5 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

29. Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Johannes V. Swinnen, Margaret M. Centenera, Lisa G. Horvath, Wayne D. Tilley, David J. Lynn, Marten F. Snel, Paul J. Trim, Luke A. Selth, Zeyad D. Nassar, Etienne Waelkens, Rita Derua, Thomas Gevaert, James G. Kench, Jurgen Stahl, Rajdeep Das, Katarzyna Bloch, Frank Vanderhoydonc, Jonas Dehairs, Max Moldovan, David Waltregny, Muralidhararao Bagadi, Xander Spotbeen, Shadrack M. Mutuku, Swati Irani, Andrew D. Vincent, Jelle Machiels, Chui Yan Mah, and Lisa M. Butler

Abstract

Results of lipid association analyses

Published
2023
Full Text
View/download PDF

30. Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Johannes V. Swinnen, Margaret M. Centenera, Lisa G. Horvath, Wayne D. Tilley, David J. Lynn, Marten F. Snel, Paul J. Trim, Luke A. Selth, Zeyad D. Nassar, Etienne Waelkens, Rita Derua, Thomas Gevaert, James G. Kench, Jurgen Stahl, Rajdeep Das, Katarzyna Bloch, Frank Vanderhoydonc, Jonas Dehairs, Max Moldovan, David Waltregny, Muralidhararao Bagadi, Xander Spotbeen, Shadrack M. Mutuku, Swati Irani, Andrew D. Vincent, Jelle Machiels, Chui Yan Mah, and Lisa M. Butler

Abstract

Supplementary Figures S1-S6

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Supplementary Figure 3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Published
2023
Full Text
View/download PDF

32. Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Johannes V. Swinnen, Margaret M. Centenera, Lisa G. Horvath, Wayne D. Tilley, David J. Lynn, Marten F. Snel, Paul J. Trim, Luke A. Selth, Zeyad D. Nassar, Etienne Waelkens, Rita Derua, Thomas Gevaert, James G. Kench, Jurgen Stahl, Rajdeep Das, Katarzyna Bloch, Frank Vanderhoydonc, Jonas Dehairs, Max Moldovan, David Waltregny, Muralidhararao Bagadi, Xander Spotbeen, Shadrack M. Mutuku, Swati Irani, Andrew D. Vincent, Jelle Machiels, Chui Yan Mah, and Lisa M. Butler

Abstract

Patient and sample clinical characteristics

Published
2023
Full Text
View/download PDF

33. Supplementary Table and Figure Legends from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Supplementary Table and Figure Legends from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 4 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Supplementary Figure 4 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Figure 1 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 1 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Supplementary Figure 1 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Published
2023
Full Text
View/download PDF

37. Supplementary Table 2 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Table 2 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 3 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Figure 3 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

David J. Horsfall, Wayne D. Tilley, Robert L. Sutherland, Gail P. Risbridger, Judith A. Clements, Hong Wang, Ying Dong, James G. Kench, Hemamali Samaratunga, Peter D. Sutherland, Villis R. Marshall, Penelope A. Cohen, Thomas J. Dodd, Shalini Jindal, Tina Bianco-Miotto, and Carmela Ricciardelli

Abstract

Supplementary Table 1 from Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Published
2023
Full Text
View/download PDF

40. Data from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Susan J. Clark, Robert L. Sutherland, Miguel A. Peinado, Regina Mayor, Anne-Maree Haynes, Ruth Pe Benito, Susan M. Henshall, James G. Kench, Toby Hulf, Marcel W. Coolen, Bruce Tabor, Lisa G. Horvath, Kate I. Patterson, Aaron L. Statham, Jenny Z. Song, Wenjia Qu, Clare Stirzaker, and James Devaney

Abstract

Background: Previously, we showed that gene suppression commonly occurs across chromosome 2q14.2 in colorectal cancer, through a process of long-range epigenetic silencing (LRES), involving a combination of DNA methylation and repressive histone modifications. We now investigate whether LRES also occurs in prostate cancer across this 4-Mb region and whether differential DNA methylation of 2q14.2 genes could provide a regional panel of prostate cancer biomarkers.Methods: We used highly sensitive DNA methylation headloop PCR assays that can detect 10 to 25 pg of methylated DNA with a specificity of at least 1:1,000, and chromatin immunoprecipitation assays to investigate regional epigenetic remodeling across 2q14.2 in prostate cancer, in a cohort of 195 primary prostate tumors and 90 matched normal controls.Results: Prostate cancer cells exhibit concordant deacetylation and methylation of histone H3 Lysine 9 (H3K9Ac and H3K9me2, respectively), and localized DNA hypermethylation of EN1, SCTR, and INHBB and corresponding loss of H3K27me3. EN1 and SCTR were frequently methylated (65% and 53%, respectively), whereas INHBB was less frequently methylated.Conclusions: Consistent with LRES in colorectal cancer, we found regional epigenetic remodeling across 2q14.2 in prostate cancer. Concordant methylation of EN1 and SCTR was able to differentiate cancer from normal (P < 0.0001) and improved the diagnostic specificity of GSTP1 methylation for prostate cancer detection by 26%.Impact: For the first time we show that DNA methylation of EN1 and SCTR promoters provide potential novel biomarkers for prostate cancer detection and in combination with GSTP1 methylation can add increased specificity and sensitivity to improve diagnostic potential. Cancer Epidemiol Biomarkers Prev; 20(1); 148–59. ©2011 AACR.

Published
2023
Full Text
View/download PDF

41. Data from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Background: Epigenetic alterations are common in prostate cancer, yet how these modifications contribute to carcinogenesis is poorly understood. We investigated whether specific histone modifications are prognostic for prostate cancer relapse, and whether the expression of epigenetic genes is altered in prostate tumorigenesis.Methods: Global levels of histone H3 lysine-18 acetylation (H3K18Ac) and histone H3 lysine-4 dimethylation (H3K4diMe) were assessed immunohistochemically in a prostate cancer cohort of 279 cases. Epigenetic gene expression was investigated in silico by analysis of microarray data from 23 primary prostate cancers (8 with biochemical recurrence and 15 without) and 7 metastatic lesions.Results: H3K18Ac and H3K4diMe are independent predictors of relapse-free survival, with high global levels associated with a 1.71-fold (P < 0.0001) and 1.80-fold (P = 0.006) increased risk of tumor recurrence, respectively. High levels of both histone modifications were associated with a 3-fold increased risk of relapse (P < 0.0001). Epigenetic gene expression profiling identified a candidate gene signature (DNMT3A, MBD4, MLL2, MLL3, NSD1, and SRCAP), which significantly discriminated nonmalignant from prostate tumor tissue (P = 0.0063) in an independent cohort.Conclusions: This study has established the importance of histone modifications in predicting prostate cancer relapse and has identified an epigenetic gene signature associated with prostate tumorigenesis.Impact: Our findings suggest that targeting the epigenetic enzymes specifically involved in a particular solid tumor may be a more effective approach. Moreover, testing for aberrant expression of epigenetic genes such as those identified in this study may be beneficial in predicting individual patient response to epigenetic therapies. Cancer Epidemiol Biomarkers Prev; 19(10); 2611–22. ©2010 AACR.

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 4 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Carmela Ricciardelli, David J. Horsfall, Wayne D. Tilley, Lisa M. Butler, Judith A. Clements, Gail P. Risbridger, Howard I. Scher, William L. Gerald, Susan M. Henshall, Robert L. Sutherland, Villis R. Marshall, Phillip D. Stricker, James G. Kench, Lisa G. Horvath, Wendy A. Raymond, Natalie K. Ryan, Melissa A. O'Loughlin, Marie A. Pickering, Mervyn Thomas, Tanya K. Day, Shalini Jindal, Grant Buchanan, Karen Chiam, and Tina Bianco-Miotto

Abstract

Supplementary Figure 4 from Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Published
2023
Full Text
View/download PDF

43. Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Johannes V. Swinnen, Margaret M. Centenera, Lisa G. Horvath, Wayne D. Tilley, David J. Lynn, Marten F. Snel, Paul J. Trim, Luke A. Selth, Zeyad D. Nassar, Etienne Waelkens, Rita Derua, Thomas Gevaert, James G. Kench, Jurgen Stahl, Rajdeep Das, Katarzyna Bloch, Frank Vanderhoydonc, Jonas Dehairs, Max Moldovan, David Waltregny, Muralidhararao Bagadi, Xander Spotbeen, Shadrack M. Mutuku, Swati Irani, Andrew D. Vincent, Jelle Machiels, Chui Yan Mah, and Lisa M. Butler

Abstract

Dysregulated lipid metabolism is a prominent feature of prostate cancer that is driven by androgen receptor (AR) signaling. Here we used quantitative mass spectrometry to define the “lipidome” in prostate tumors with matched benign tissues (n = 21), independent unmatched tissues (n = 47), and primary prostate explants cultured with the clinical AR antagonist enzalutamide (n = 43). Significant differences in lipid composition were detected and spatially visualized in tumors compared with matched benign samples. Notably, tumors featured higher proportions of monounsaturated lipids overall and elongated fatty acid chains in phosphatidylinositol and phosphatidylserine lipids. Significant associations between lipid profile and malignancy were validated in unmatched samples, and phospholipid composition was characteristically altered in patient tissues that responded to AR inhibition. Importantly, targeting tumor-related lipid features via inhibition of acetyl-CoA carboxylase 1 significantly reduced cellular proliferation and induced apoptosis in tissue explants. This characterization of the prostate cancer lipidome in clinical tissues reveals enhanced fatty acid synthesis, elongation, and desaturation as tumor-defining features, with potential for therapeutic targeting.Significance:This study identifies malignancy and treatment-associated changes in lipid composition of clinical prostate cancer tissues, suggesting that mediators of these lipidomic changes could be targeted using existing metabolic agents.

Published
2023
Full Text
View/download PDF

44. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition

Author

Butler, Lisa M., primary, Mah, Chui Yan, additional, Machiels, Jelle, additional, Vincent, Andrew D., additional, Irani, Swati, additional, Mutuku, Shadrack M., additional, Spotbeen, Xander, additional, Bagadi, Muralidhararao, additional, Waltregny, David, additional, Moldovan, Max, additional, Dehairs, Jonas, additional, Vanderhoydonc, Frank, additional, Bloch, Katarzyna, additional, Das, Rajdeep, additional, Stahl, Jurgen, additional, Kench, James G., additional, Gevaert, Thomas, additional, Derua, Rita, additional, Waelkens, Etienne, additional, Nassar, Zeyad D., additional, Selth, Luke A., additional, Trim, Paul J., additional, Snel, Marten F., additional, Lynn, David J., additional, Tilley, Wayne D., additional, Horvath, Lisa G., additional, Centenera, Margaret M., additional, and Swinnen, Johannes V., additional

Published
2021
Full Text
View/download PDF

45. Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

Peter Sutherland, Tom Dodd, Shalini Jindal, Hong Wang, Carmela Ricciardelli, Wayne D. Tilley, Judith A. Clements, Robert L. Sutherland, Hemamali Samaratunga, Penelope Cohen, Villis R. Marshall, Tina Bianco-Miotto, Ying Dong, James G. Kench, Gail P. Risbridger, and David J. Horsfall

Subjects
Male, medicine.medical_specialty, Pathology, Epidemiology, medicine.medical_treatment, Urology, Gene Expression, Specimen Handling, Prostate cancer, Prostate, Biopsy, Biomarkers, Tumor, medicine, Humans, RNA, Neoplasm, Aged, Prostatectomy, Tissue microarray, medicine.diagnostic_test, Reverse Transcriptase Polymerase Chain Reaction, business.industry, Prostatic Neoplasms, Robotics, Middle Aged, Prostate-Specific Antigen, medicine.disease, Immunohistochemistry, Prostate-specific antigen, medicine.anatomical_structure, Oncology, Receptors, Androgen, Biomarker (medicine), Laparoscopy, business
Abstract

Background: Knowledge of preanalytic conditions that biospecimens are subjected to is critically important because novel surgical procedures, tissue sampling, handling, and storage might affect biomarker expression or invalidate tissue samples as analytes for some technologies. Methods: We investigated differences in RNA quality, gene expression by quantitative real-time PCR, and immunoreactive protein expression of selected prostate cancer biomarkers between tissues from retropubic radical prostatectomy (RRP) and robot-assisted laparoscopic prostatectomy (RALP). Sections of tissue microarray of 23 RALP and 22 RRP samples were stained with antibodies to androgen receptor (AR) and prostate-specific antigen (PSA) as intersite controls, and 14 other candidate biomarkers of research interest to three laboratories within the Australian Prostate Cancer BioResource tissue banking network. Quantitative real-time PCR was done for AR, PSA (KLK3), KLK2, KLK4, and HIF1A on RNA extracted from five RALP and five RRP frozen tissue cores. Results: No histologic differences were observed between RALP and RRP tissue. Biomarker staining grouped these samples into those with increased (PSA, CK8/18, CKHMW, KLK4), decreased (KLK2, KLK14), or no change in expression (AR, ghrelin, Ki67, PCNA, VEGF-C, PAR2, YB1, p63, versican, and chondroitin 0-sulfate) in RALP compared with RRP tissue. No difference in RNA quality or gene expression was detected between RALP and RRP tissue. Conclusions: Changes in biomarker expression between RALP and RRP tissue exist at the immunoreactive protein level, but the etiology is unclear. Impact: Future studies should account for changes in biomarker expression when using RALP tissues, and mixed cohorts of RALP and RRP tissue should be avoided. Cancer Epidemiol Biomarkers Prev; 19(7); 1755–65. ©2010 AACR.

Published
2010
Full Text
View/download PDF

46. Abstract 1156: A molecular pre-operative prognostic nomogram for resectable pancreatic cancer.

Author

Chang, David K., primary, Pinese, Mark, additional, Scarlett, Christopher J., additional, Pajic, Marina, additional, Colvin, Emily K., additional, Johns, Amber L., additional, Wu, Jianmin, additional, Cowley, Mark J., additional, Humphris, Jeremy L., additional, Chou, Angela, additional, Nguyen, Nam Q., additional, Nagrial, Adnan M., additional, Chantrill, Lorraine, additional, Chin, Venessa T., additional, Musgrove, Elizabeth A., additional, Altekruse, Sean, additional, Gill, Anthony J., additional, Kench, James G., additional, and Biankin, Andrew V., additional

Published
2013
Full Text
View/download PDF

47. Abstract 1156: A molecular pre-operative prognostic nomogram for resectable pancreatic cancer

Author

Jeremy L. Humphris, Christopher J. Scarlett, Jianmin Wu, David K. Chang, Nam Q. Nguyen, Lorraine A. Chantrill, Adnan Nagrial, Marina Pajic, Emily K. Colvin, Amber L. Johns, Angela Chou, Mark Pinese, Sean F. Altekruse, Anthony J. Gill, Elizabeth A. Musgrove, James G. Kench, Venessa T. Chin, Mark J. Cowley, and Andrew V. Biankin

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Prognostic variable, business.industry, Cancer, Disease, Nomogram, medicine.disease, Surgery, Quality of life, Pancreatic cancer, Internal medicine, Medicine, Biomarker (medicine), business, Prospective cohort study
Abstract

Purpose: Defining clinically and biologically relevant phenotypes to inform treatment decisions in other cancers have led to substantial improvements in overall outcomes. About 80% of patients with pancreatic cancer (PC) succumb to the disease despite curative resection, many of whom recur within 6 months of surgery. These early recurrences demonstrate that current staging is inadequate and that there is a clear need to better define prognostic phenotypes prior to significant intervention. This study aimed to evaluate the potential clinical utility of biologically relevant molecules as prognostic factors in resected PC to define strategies that may improve current preoperative staging accuracy and inform treatment decisions. Method: We assessed the relationship of aberrant expression of two pro-metastatic calcium-binding proteins, S100A2 and S100A4 with disease-specific survival in four independent cohorts of patients (total n = 547) who underwent operative resection for PC. A preoperative nomogram using pre-operatively assessable variables including biomarkers was derived and was compared to traditional prognostic variables and the postoperative nomogram. Results: High S100A2 and S100A4 expressions were an independent poor prognostic factor in both the training (n = 76; HR = 2.00, 95% CI = 1.15 - 3.49, P = 0.0216 and HR = 3.34, 95% CI = 1.69 - 6.62, P = 0.0005 respectively) and validation (n = 316; HR = 1.73, 95% CI = 1.20 - 2.48, P = 0.0030 and HR = 1.65, 95% CI = 1.23 - 2.22, P = 0.0009 respectively) cohorts. These results were further validated in a prospective cohort (ICGC-APGI, n = 100) and another retrospective population based cohort (NCI SEER, n = 55). Aberrant expression of S100A2/A4 protein again stratified the cohorts into 3 distinct prognostic groups. A preoperative nomogram using only variables that could be measured preoperatively (age, tumour size, tumour location and molecular biomarkers), predicted survival better than nomograms derived using clinico-pathological variables, which are only determinable after surgery. A proof-of-principle study demonstrated that biomarker expression can be reliably assessed in preoperative EUS-FNA cell block samples. Conclusion: S100A4 and S100A2 are one of the very few biomarkers that have been independently validated in multiple patient cohorts. Their aberrant expression stratifies PC into distinct prognostic groups and potentially enables more accurate preoperative prognostication through a nomogram. Biomarker assessment potentially enables accurate preoperative prognostication, which is more accurate than current staging methods. The development and application of such nomograms has the potential to improve patient selection for surgery and assist clinicians in making “tie-breaker” decisions that would ultimately improve the overall survival and quality of life for patients with PC. Citation Format: David K. Chang, Mark Pinese, Christopher J. Scarlett, Marina Pajic, Emily K. Colvin, Amber L. Johns, Jianmin Wu, Mark J. Cowley, Jeremy L. Humphris, Angela Chou, Nam Q. Nguyen, Adnan M. Nagrial, Lorraine Chantrill, Venessa T. Chin, Elizabeth A. Musgrove, Sean Altekruse, Anthony J. Gill, James G. Kench, Andrew V. Biankin. A molecular pre-operative prognostic nomogram for resectable pancreatic cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1156. doi:10.1158/1538-7445.AM2013-1156

Published
2013
Full Text
View/download PDF

48. Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

Author

Devaney, James, primary, Stirzaker, Clare, additional, Qu, Wenjia, additional, Song, Jenny Z., additional, Statham, Aaron L., additional, Patterson, Kate I., additional, Horvath, Lisa G., additional, Tabor, Bruce, additional, Coolen, Marcel W., additional, Hulf, Toby, additional, Kench, James G., additional, Henshall, Susan M., additional, Pe Benito, Ruth, additional, Haynes, Anne-Maree, additional, Mayor, Regina, additional, Peinado, Miguel A., additional, Sutherland, Robert L., additional, and Clark, Susan J., additional

Published
2011
Full Text
View/download PDF

49. Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development

Author

Bianco-Miotto, Tina, primary, Chiam, Karen, additional, Buchanan, Grant, additional, Jindal, Shalini, additional, Day, Tanya K., additional, Thomas, Mervyn, additional, Pickering, Marie A., additional, O'Loughlin, Melissa A., additional, Ryan, Natalie K., additional, Raymond, Wendy A., additional, Horvath, Lisa G., additional, Kench, James G., additional, Stricker, Phillip D., additional, Marshall, Villis R., additional, Sutherland, Robert L., additional, Henshall, Susan M., additional, Gerald, William L., additional, Scher, Howard I., additional, Risbridger, Gail P., additional, Clements, Judith A., additional, Butler, Lisa M., additional, Tilley, Wayne D., additional, Horsfall, David J., additional, and Ricciardelli, Carmela, additional

Published
2010
Full Text
View/download PDF

50. Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies

Author

Ricciardelli, Carmela, primary, Bianco-Miotto, Tina, additional, Jindal, Shalini, additional, Dodd, Thomas J., additional, Cohen, Penelope A., additional, Marshall, Villis R., additional, Sutherland, Peter D., additional, Samaratunga, Hemamali, additional, Kench, James G., additional, Dong, Ying, additional, Wang, Hong, additional, Clements, Judith A., additional, Risbridger, Gail P., additional, Sutherland, Robert L., additional, Tilley, Wayne D., additional, and Horsfall, David J., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results